Pharmafile Logo
Pharmafocus logo
Advanced Search

blincyto

Showing 6 posts of 6 posts found.

NICE recommends Amgen’s Blincyto in rare acute lymphoblastic leukaemia sub-population

June 19, 2019
Research and Development, Sales and Marketing Amgen, Cancer, NICE, acute lymphoblastic leukaemia, blincyto, pharma

Patients on the NHS in England and Wales will now be able to access Amgen’s Blincyto (blinatumomab) after NICE reveals …

News
amgen_hq

Amgen’s Blincyto secures expanded indication in Europe for acute lymphoblastic leukaemia

January 23, 2019
Research and Development, Sales and Marketing Ammgen, Cancer, Europe, European Commission, blincyto, leukaemia, pharma

The European Commission has chosen to expand the authorised indication for Amgen’s Blincyto (blinatumomab) in the region, it has emerged, …

News
amgen_flag

Amgen’s leukaemia treatment given FDA thumbs up for use in paediatric patients

September 2, 2016
Medical Communications, Sales and Marketing Amgen, FDA, blincyto, leukaemia

Amgen has announced that the FDA has approved the supplemental Biologics License Application for Blincyto (blinatumomab) in the treatment of …

News
amgen_flag

FDA grants priority review for Amgen leukaemia drug

May 4, 2016
Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric

Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …

News
EU flag

Novartis and Amgen drugs signed-off by European Commission

November 24, 2015
Manufacturing and Production Amgen, Entresto, European Commission, Novartis, blincyto

The European governing body, the European Commission, has approved the Novartis drug Entresto for heart failure and Amgen’s Blincyto for …

News
Amgen image

Speedy FDA nod for Amgen leukaemia drug

December 5, 2014
Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia

The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …

News

Latest content

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024